Skip to Main Content

Author Details

Daniel J Skiest
University of Massachusetts Medical School-Baystate
1988
101
36
PMIDPaper TitleJournal TitlePublished Year
36541802Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control.J Virol2023
36877848HIV post-treatment controllers have distinct immunological and virological features.Proc Natl Acad Sci U S A2023
35475258Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).EClinicalMedicine2022
34127579Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.AIDS2021
33631066Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.N Engl J Med2021
32645158Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.J Infect Dis2020
31538917Possible Prognostic Value of Serial Brain MRIs in Powassan Virus Encephalitis.Emerg Infect Dis2019
29593048Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.J Virol2018
30024859HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.J Clin Invest2018
30085241The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.J Infect Dis2018
29373393Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.J Acquir Immune Defic Syndr2018
29091975Treatment Trends and Outcomes in Healthcare-Associated Pneumonia.J Hosp Med2017
28476270Corrigendum to 'An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone' [Journal of Substance Abuse Treatment 47 (2014) 35-40].J Subst Abuse Treat2017
27048748Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.Clin Infect Dis2016
25395187Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.J Infect Dis2015
26288843Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.EBioMedicine2015
25558075Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia.J Antimicrob Chemother2015
24108450Toxoplasma encephalitis in an HIV-infected patient on highly active antiretroviral therapy despite sustained immune response.Int J STD AIDS2014
25222889Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients?Infect Control Hosp Epidemiol2014
25240704Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Contemp Clin Trials2014
24674234An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.J Subst Abuse Treat2014
24498090Using highly detailed administrative data to predict pneumonia mortality.PLoS One2014
23219109Successful kidney transplantation from a hepatitis B surface antigen-positive donor to an antigen-negative recipient using a novel vaccination regimen.Am J Kidney Dis2013
22689239Genome sequence of Listeria monocytogenes 07PF0776, a cardiotropic serovar 4b strain.J Bacteriol2012
21266727Evidence for subpopulations of Listeria monocytogenes with enhanced invasion of cardiac cells.J Med Microbiol2011
21684853Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.HIV Clin Trials2011
21641801Spectrum of breast disease encountered in HIV-positive patients at a community teaching hospital.Breast2011
20009764Use of HIV resistance testing after prolonged treatment interruption.J Acquir Immune Defic Syndr2010
20798402Low prevalence of primary HIV resistance in western Massachusetts.J Int Assoc Physicians AIDS Care (Chic)2010
20533570Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).J Hosp Med2010
20501925Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.JAMA2010
20237308Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.Neurology2010
19209454Subacute onset of paralysis in a person with AIDS.AIDS Read2009
19076107Nomenclature and definitions for emergency department human immunodeficiency virus (HIV) testing: report from the 2007 conference of the National Emergency Department HIV Testing Consortium.Acad Emerg Med2009
19183506Survey of physician knowledge regarding antiretroviral medications in hospitalized HIV-infected patients.J Int AIDS Soc2009
18097230Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.AIDS2008
31547639Reply to Cooper et al.J Infect Dis2008
18724805CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.AIDS Res Hum Retroviruses2008
18931631Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170.J Acquir Immune Defic Syndr2008
18975443Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndrome.AIDS Read2008
18574129Choriocarcinoma in an AIDS patient--relapsing but not fatal.Int J STD AIDS2008
18558886Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.Clin Infect Dis2008
18645516Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients.J Acquir Immune Defic Syndr2008
18377810Methicillin-resistant Staphylococcus aureus: from the hospital to the community.Curr Infect Dis Rep2008
17243069Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.Clin Infect Dis2007
17893418Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients.Am J Health Syst Pharm2007
18071179High recurrence rate of CA-MRSA skin and soft tissue infections.Arch Intern Med2007
17672013Images in HIV/AIDS. Invasive aspergillosis presenting as a neck mass in a person with HIV/AIDS.AIDS Read2007
17317667The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication.J Biol Chem2007
17507324Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.HIV Clin Trials2007
  • 1 - 50 of 101

Recommended Authors

University of Kansas Medical Center
Career Start Year 2006
Number of shared co-authors 1
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 0
Goethe University Frankfurt, University Hospital
Career Start Year 2003
Number of shared co-authors 0
University of Minnesota
Career Start Year 2003
Number of shared co-authors 3
Vitalant Research Institute, USA University of California san francisco
Career Start Year 2001
Number of shared co-authors 4
Northwestern University Feinberg School of Medicine
Career Start Year 2000
Number of shared co-authors 5
Lausanne University Hospital, University of Lausanne
Career Start Year 1999
Number of shared co-authors 3
Emory University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Hospital Chemnitz
Career Start Year 1991
Number of shared co-authors 0
Hospital Universitario de Guadalajara
Career Start Year 1991
Number of shared co-authors 0
Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM)
Career Start Year 1991
Number of shared co-authors 0
Johns Hopkins School of Medicine, Johns Hopkins University
Career Start Year 1990
Number of shared co-authors 13
Mount Sinai Health System and University Health Network
Career Start Year 1989
Number of shared co-authors 0
Harvard School of Public Health
Career Start Year 1989
Number of shared co-authors 7
University Medical Center Utrecht
Career Start Year 1988
Number of shared co-authors 2
La Paz University Hospital
Career Start Year 1988
Number of shared co-authors 3
Hospital Clinico San Carlos-IdiSSC, Universidad Complutense
Career Start Year 1988
Number of shared co-authors 3
University of Nebraska Medical Center
Career Start Year 1987
Number of shared co-authors 12
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1985
Number of shared co-authors 5
Yale University
Career Start Year 1984
Number of shared co-authors 2
Perelman School of Medicine, the University of Pennsylvania
Career Start Year 1983
Number of shared co-authors 5
Division of Clinical Research, National Institutes of Allergy and Infectious Diseases
Career Start Year 1981
Number of shared co-authors 3
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Career Start Year 1979
Number of shared co-authors 7
University of Miami, Miller School of Medicine
Career Start Year 1977
Number of shared co-authors 3
University of Michigan ann arbor
Career Start Year 1976
Number of shared co-authors 5
University of California San Diego
Career Start Year 1975
Number of shared co-authors 6
Johns Hopkins Bloomberg School of Public Health
Career Start Year 1973
Number of shared co-authors 7
University of California berkeley
Career Start Year 1971
Number of shared co-authors 0
Center for AIDS Research, University of California San Diego
Career Start Year 1970
Number of shared co-authors 15
Wistar Institute
Career Start Year 1958
Number of shared co-authors 8

Collaborators

University of Massachusetts Amherst
Co-authored papers 8
Institute for Global Health Sciences, University of California san francisco
Co-authored papers 6
Co-authored papers 6
Co-authored papers 5
Co-authored papers 3
University of California san francisco
Co-authored papers 3
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 3
Co-authored papers 2
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
University of Washington
Co-authored papers 2
Weizmann Institute of Science
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
University of Texas Southwestern Medical Center
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Duke Clinical Research Institute, Duke University
Co-authored papers 1
Rutgers New Jersey Medical School
Co-authored papers 1
Emory University
Co-authored papers 1
Johns Hopkins
Co-authored papers 1
7 George Washington University
Co-authored papers 1
Tufts University School of Medicine, MA Baystate Medical Center
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Vir Biotechnology Inc.
Co-authored papers 1